financetom
Business
financetom
/
Business
/
American Tower's Q1 Adjusted Funds From Operations, Operating Revenue Rise; 2024 AFFO Outlook Lifted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Tower's Q1 Adjusted Funds From Operations, Operating Revenue Rise; 2024 AFFO Outlook Lifted
Apr 30, 2024 5:48 AM

08:20 AM EDT, 04/30/2024 (MT Newswires) -- American Tower ( AMT ) reported Q1 adjusted funds from operations Tuesday of $2.79 per share, up from $2.54 a year earlier.

Analysts polled by Capital IQ expected $2.54.

Operating revenue for the quarter ended March 31 was $2.83 billion, compared with $2.77 billion a year earlier. Analysts polled by Capital IQ expected $2.80 billion.

The company said it now expects fiscal 2024 adjusted funds from operations of $10.30 to $10.53 per share, versus $10.21 to $10.45 per share anticipated previously. Analysts polled by Capital IQ expect $10.33.

American Tower's ( AMT ) shares were up 2.7% in recent Tuesday premarket activity.

Price: 179.75, Change: +4.76, Percent Change: +2.72

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Oct 17, 2024
09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases. The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now...
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...
BRIEF-Xerox Acquires ITsavvy To Grow IT Services Presence
BRIEF-Xerox Acquires ITsavvy To Grow IT Services Presence
Oct 17, 2024
Oct 17 (Reuters) - Xerox Holdings Corp ( XRX ): * XEROX ACQUIRES ITSAVVY TO GROW IT SERVICES PRESENCE * XEROX HOLDINGS CORP ( XRX ) - TO ACQUIRE ITSAVVY FOR $400 MILLION * XEROX HOLDINGS CORP ( XRX ) - ACQUISITION EXPECTED TO BE IMMEDIATELY ACCRETIVE TO EPS AND FREE CASH FLOW Source text for Eikon: Further company coverage:...
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Oct 17, 2024
02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved